Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Mayuko Yamaki"'
Autor:
Toshihiko Matsumoto, Mayuko Yamaki, Yoshiko Takeshita, Yuriko Takagishi, Soichiro Omiya, Ayumi Kondo, Youichi Takano, Michiko Kobayashi, Takuya Shimane, Masaru Takahashi
Publikováno v:
Substance Use & Misuse. 56:54-60
There are a few studies on gender differences in terms of reasons and motives for methamphetamine use. Purpose/Objectives: To examine gender differences in triggers of methamphetamine use Methods: ...
Autor:
Masaru Takahashi, Mayuko Yamaki, Ayumi Kondo, Masato Hattori, Michiko Kobayashi, Takuya Shimane
Publikováno v:
Child Abuse & Neglect. 131:105763
Adverse childhood experiences (ACEs) are distressing and/or traumatic events that occur during childhood that increase the risk of negative health outcomes in adulthood.This study estimated the prevalence of ACEs in a nationwide sample of Japanese me
Autor:
Ayumi Kondo, Takuya Shimane, Masaru Takahashi, Yoshiko Takeshita, Youichi Takano, Soichiro Omiya, Yuriko Takagishi, Toshihiko Matsumoto, Mayuko Yamaki, Michiko Kobayashi
Publikováno v:
Journal of psychoactive drugs. 54(1)
This study aimed to examine the relationship between methamphetamine (MA) use and high-risk sexual behavior among newly incarcerated prisoners in Japan. We conducted a secondary analysis using cross-sectional survey data, which constituted a nationwi
Publikováno v:
Personality and Individual Differences. 141:81-85
The purpose of this study was to investigate differences in personality traits among violent, theft, and illegal drug use criminals, comparing them with normal adults. Inmates (N = 645) and normal adults (N = 4546) in Japan responded to a questionnai
Publikováno v:
Experimental Dermatology. 19:730-735
Epidermal growth factor receptor tyrosine kinase (EGFR-TK) is a transducer of mitogenic signals, and is involved in the pathogenesis and progression of a number of cancers, including non-small cell lung cancer (NSCLC). Gefitinib is an EGFR-TK inhibit
Publikováno v:
Experimental dermatology. 19(8)
Epidermal growth factor receptor tyrosine kinase (EGFR-TK) is a transducer of mitogenic signals, and is involved in the pathogenesis and progression of a number of cancers, including non-small cell lung cancer (NSCLC). Gefitinib is an EGFR-TK inhibit